cadenas

ITCC - Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

  • A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML

  • A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma

  • A Phase 1b, Dose Escalation Study of Abemaciclib in Combination with Temozolomide and Irinotecan (triplet escalation) and Abemaciclib in combination with Temozolomidea

  • A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

  • A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

  • A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma

  • ITCC-091 FaR-RMS

    Solid Tumor

    FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma

33 - 39 sur 39
<< Premier 1 2 3 4 5 Suivant > Dernier >>